Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience

被引：0
|
作者：
Kelaidi, C. [1 ]
Park, S. [1 ]
Tamburini, J. [1 ]
Sapena, R. [1 ]
Raffoux, E. [1 ]
Beyne-Rauzy, O. [1 ]
Coiteux, V. [1 ]
Aljassem, L. [1 ]
Prebet, T. [1 ]
Legros, L. [1 ]
Stamatoullas, A. [1 ]
Sanhes, L. [1 ]
Delarue, R. [1 ]
Dreyfus, F. [1 ]
Fenaux, P. [1 ]
机构：
[1] GFM, Bobigny, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70192-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：S124 / S124
页数：1
相关论文
共 50 条
  • [21] Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
    Jan Krönke
    Emma C. Fink
    Paul W. Hollenbach
    Kyle J. MacBeth
    Slater N. Hurst
    Namrata D. Udeshi
    Philip P. Chamberlain
    D. R. Mani
    Hon Wah Man
    Anita K. Gandhi
    Tanya Svinkina
    Rebekka K. Schneider
    Marie McConkey
    Marcus Järås
    Elizabeth Griffiths
    Meir Wetzler
    Lars Bullinger
    Brian E. Cathers
    Steven A. Carr
    Rajesh Chopra
    Benjamin L. Ebert
    Nature, 2015, 523 : 183 - 188
  • [22] Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
    Kroenke, Jan
    Fink, Emma C.
    Hollenbach, Paul W.
    MacBeth, Kyle J.
    Hurst, Slater N.
    Udeshi, Namrata D.
    Chamberlain, Philip P.
    Mani, D. R.
    Man, Hon Wah
    Gandhi, Anita K.
    Svinkina, Tanya
    Schneider, Rebekka K.
    McConkey, Marie
    Jaeras, Marcus
    Griffiths, Elizabeth
    Wetzler, Meir
    Bullinger, Lars
    Cathers, Brian E.
    Carr, Steven A.
    Chopra, Rajesh
    Ebert, Benjamin L.
    NATURE, 2015, 523 (7559) : 183 - U102
  • [23] Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Schmidt, Aline
    Visanica, Sorin
    Eclache, Virginie
    Turlure, Pascal
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Rea, Delphine
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1444 - 1448
  • [24] Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Lebras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Visanica, Sorin
    Turlure, Pascal
    Guerci, Agnes
    Cabrol, Marie Paule
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Eclache, Virginie
    Chevret, Sylvie
    Fenaux, Pierre
    BLOOD, 2010, 116 (21) : 429 - 430
  • [25] Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
    Gurnari, Carmelo
    Piciocchi, Alfonso
    Soddu, Stefano
    Bonanni, Fabrizio
    Scalzulli, Emilia
    Niscola, Pasquale
    Di Veroli, Ambra
    Piccioni, Anna Lina
    Piedimonte, Monica
    Maiorana, Gianluca
    Salutari, Prassede
    Cicconi, Laura
    Santopietro, Michelina
    Gumenyuk, Svitlana
    Sarlo, Chiara
    Fenu, Susanna
    Tafuri, Agostino
    Latagliata, Roberto
    Fianchi, Luana
    Criscuolo, Marianna
    Maciejewski, Jaroslaw P.
    Maurillo, Luca
    Buccisano, Francesco
    Breccia, Massimo
    Voso, Maria Teresa
    BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [26] Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
    Carmelo Gurnari
    Alfonso Piciocchi
    Stefano Soddu
    Fabrizio Bonanni
    Emilia Scalzulli
    Pasquale Niscola
    Ambra Di Veroli
    Anna Lina Piccioni
    Monica Piedimonte
    Gianluca Maiorana
    Prassede Salutari
    Laura Cicconi
    Michelina Santopietro
    Svitlana Gumenyuk
    Chiara Sarlo
    Susanna Fenu
    Agostino Tafuri
    Roberto Latagliata
    Luana Fianchi
    Marianna Criscuolo
    Jaroslaw P. Maciejewski
    Luca Maurillo
    Francesco Buccisano
    Massimo Breccia
    Maria Teresa Voso
    Blood Cancer Journal, 12
  • [27] Correlation between occurrence of cytopeniasand response to lenalidomide therapy in del 5q MDS patients
    Sekeres, A.
    Maciejewski, J. P.
    Giagounidis, A.
    Wride, K.
    Knight, R.
    List, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 83 - 84
  • [28] Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q)
    Fink, Emma C.
    Kroenke, Jan
    Hurst, Slater N.
    Udeshi, Namrata D.
    Svinkina, Tanya
    Schneider, Rebekka K.
    McConkey, Marie E.
    Jaeras, Marcus
    Bullinger, Lars
    Carr, Steven A.
    Ebert, Benjamin L.
    BLOOD, 2014, 124 (21)
  • [29] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [30] Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
    Toribio Castello, Sofia M.
    Lopez-Cadenas, Felix
    Preudhomme, Claude
    Villaverde Ramiro, Angela
    Fenwarth, Laurene
    Lumbreras, Eva
    Gonzalez, Teresa
    Del Rey, Monica
    Xicoy, Blanca
    Renneville, Aline
    Sanchez-Garcia, Joaquin
    Coll, Rosa
    Slama, Bohrane
    Angel Hernandez-Rivas, Jose
    Thepot, Sylvain
    Bernal, Teresa
    Guerci-Bresler, Agnes
    Gotze, Katharina
    Maria Hernandez-Rivas, Jesus
    Fenaux, Pierre
    Del Canizo, Consuelo
    Diez-Campelo, Maria
    BLOOD, 2022, 140 : 9740 - 9743
12345